EGFR and non-small cell lung carcinoma: In addition, exosomes derived from M2 type TAMs were also showed to confer osimertinib resistance in NSCLC through MSTRG.292666.16‐​miR‐6836‐​5p‐MAPK8IP3 axis, suggesting that targeting TAMs may help to circumvent resistance of EGFR-TKIs [384, 385].